IntuitionLabs：2025年人工智能与美国制药行业监管事务的未来研究报告（英文版）

Artificial Intelligence (AI) is poised to redefine regulatory affairs in the pharmaceutical sector. Regulatory affairs encompass the end-to-end process of drug approvals and oversight – from preparing submissions to post-market safety monitoring – all under stringent regulations. In recent years, pharma companies have widely adopted AI and machine learning (ML) tools to streamline these processes (Regulatory Concerns for AI: 2024 Trends) (Using AI to Boost Efficiency and Ensure Regulatory Com